{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T05:34:17Z","timestamp":1736919257686,"version":"3.33.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2003,9,1]],"date-time":"2003-09-01T00:00:00Z","timestamp":1062374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2003,9]]},"DOI":"10.2515\/therapie:2003074","type":"journal-article","created":{"date-parts":[[2007,3,16]],"date-time":"2007-03-16T14:17:07Z","timestamp":1174054627000},"page":"457-462","source":"Crossref","is-referenced-by-count":8,"title":["Analyse r\u00e9trospective des effets ind\u00e9sirables de l\u2019infliximab dans un service hospitalier de rhumatologie"],"prefix":"10.1016","volume":"58","author":[{"given":"Cendrine","family":"Cabou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haleh","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Cantagrel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Mazi\u00e8res","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 4","key":"10.2515\/therapie:2003074_bb1315","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.1365-2036.1999.00027.x","article-title":"Review article: safety of infliximab in clinicals trials","volume":"13","author":"Hanauer","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"year":"2002","series-title":"Remicade\u00ae. Dictionnaire Vidal","key":"10.2515\/therapie:2003074_bb1320"},{"key":"10.2515\/therapie:2003074_bb1325","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0140-6736(02)07718-8","article-title":"Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis","volume":"9306","author":"Day","year":"2002","journal-title":"Lancet"},{"key":"10.2515\/therapie:2003074_bb1330","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"10.2515\/therapie:2003074_bb1335","first-page":"111","article-title":"Imputabilit\u00e9 des effets inattendus ou toxiques des m\u00e9dicaments","volume":"40","author":"Begaud","year":"1985","journal-title":"Th\u00e9rapie"},{"issue":"Suppl. 3","key":"10.2515\/therapie:2003074_bb1340","doi-asserted-by":"crossref","first-page":"iii58","DOI":"10.1136\/ard.60.90003.iii58","article-title":"New treatment options in ankylosing spondylitis: a role for anti-TNF-alpha therapy","volume":"60","author":"Sieper","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.2515\/therapie:2003074_bb1345","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"issue":"6","key":"10.2515\/therapie:2003074_bb1350","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/ard.59.6.428","article-title":"Effects of loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study","volume":"59","author":"Van den Bosch","year":"2000","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 2","key":"10.2515\/therapie:2003074_bb1355","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1186\/ar552","article-title":"Emerging role of antitumor necrosis factor therapy in rheumatic diseases","volume":"4","author":"Kalden","year":"2002","journal-title":"Arthritis Res"},{"key":"10.2515\/therapie:2003074_bb1360","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2133.2001.04089.x","article-title":"Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate","volume":"3","author":"Ogilvie","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.2515\/therapie:2003074_bb1365","series-title":"Polyarthrite rhumato\u00efde","first-page":"2168","volume":"2","author":"Lipsky","year":"2000"},{"key":"10.2515\/therapie:2003074_bb1370","first-page":"610","article-title":"Traitement de maladies inflammatoires : s\u00e9curit\u00e9 d\u2019emploi \u00e0 long terme de l\u2019infliximab","volume":"12","author":"Schaible","year":"2001","journal-title":"Presse Med"},{"issue":"6","key":"10.2515\/therapie:2003074_bb1375","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2165\/00003495-200059060-00010","article-title":"Infliximab: a review of its use in the management of rheumatoid arthritis","volume":"59","author":"Markham","year":"2000","journal-title":"Drugs"},{"key":"10.2515\/therapie:2003074_bb1380","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial: ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.2515\/therapie:2003074_bb1385","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s002100000374","article-title":"The influence of tumor necrosis factor-alpha on the cardiovascular system of anaesthetized rats","volume":"363","author":"Tabrizchi","year":"2001","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.2515\/therapie:2003074_bb1390","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1172\/JCI116834","article-title":"Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart","volume":"5","author":"Yokoyama","year":"1993","journal-title":"J Clin Invest"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716301317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716301317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T23:48:10Z","timestamp":1736898490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716301317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,9]]}},"alternative-id":["S0040595716301317"],"URL":"https:\/\/doi.org\/10.2515\/therapie:2003074","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2003,9]]}}}